Daubers you are wrong,read the whole friggin article
Quote from the article. "The company says monthly out-of-pocket costs for the majority of patients will be $20 or less. “Bayer will ensure that no eligible patient with TRK fusion cancer will go without this highly effective therapy,” the company said in a statement."
First let K go to trial and then show efficacy. After 5 years, it is sitting on shelf after few trials, then talk annout next trial and then talk money.
K will stay there only will not come to market - IMO
Thanks for posting the link, great .news! Anyone wondering why we continue to accumulate? IPIX is on the cutting edge with a very real potential of helping millions while at the same time creating wealth for its investors. Keep the manipulated price at these levels and longs will continue to add as they are able. Go IPIX!!!